BXPHF.US Botanix Pharmaceuticals Limited

Healthcare Biotechnology USA Stocks
0.0073 USD
Close of Nov 14, 2026
0.0049 0.1149
Market cap
USD 20.2M
P/E
-
P/B
0.46x
ROE
-109.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2026.

Is BXPHF.US undervalued?

Graham number

The Graham number of Botanix Pharmaceuticals Limited cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Botanix Pharmaceuticals Limited fundamental analysis

No fundamental analysis for Botanix Pharmaceuticals Limited yet.

Botanix Pharmaceuticals Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Botanix Pharmaceuticals Limited

Botanix Pharmaceuticals Limited, a pharmaceutical company, engages in the research and commercialization of solutions for skin diseases and infections in Australia and the United States. The company's lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used to treat underarm sweating in adults and children 9 years of age and older. It also develops BTX 1503, a transdermal gel formulation, which is in Phase 3 clinical trial for the treatm…

Full company profile